Alan F. List
Independent DirectorDr. Alan F. List, M.D., had been Chief Medical Officer of Precision BioSciences, Inc. since April 26, 2021 until September 13, 2024 and serves as its Clinical Consultant & Member of Scientific Advisory Board since September 13, 2024. Dr. List serves as Member of Scientific Advisory Board at Rein Therapeutics Inc. (formerly known as Aileron Therapeutics, Inc.) since March 28, 2018. Dr. List served as the President and Chief Executive Officer at Moffitt Cancer Center. He serves as Independent Director of Tuhura Biosciences, Inc (formerly known as Morphogenesis, Inc). since October 18, 2024. Dr. List served as the Chief of the Hematologic Division at the H. Lee Moffitt Cancer Center & Research Institute, Tampa and Professor of Medicine and Oncology of the University of South Florida College of Medicine. Dr. List served as President of Society of Hematologic Oncology since 2017 until 2018. Dr. List is a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. Dr. List serves as an editor of Leukemia Research, as well as several additional scientific journals. Dr. List is an internationally recognized investigator in the biology and treatment of novel therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Dr. List served as Executive Vice President and Physician-in-Chief, the Vice Deputy Physician-in-Chief and the Chief of the Malignant Hematology Division at Moffitt, where Dr. List holds the Morsani Endowed Chair. Dr. List was the lead investigator for a study that showed important clinical results for REVLIMID(R) (lenalidomide) for MDS and multiple myeloma. Before joining to Moffitt in 2003, Dr. List served as Professor of Medicine of the University of Arizona, where Dr. List also served concurrently as the Director of the Leukemia and Blood and Marrow Transplant Program and Director of the Division of Translational/Clinical Research Program. Dr. List serves on the Board of Directors for the MDS Foundation and the Aplastic Anemia and MDS International Foundation. Dr. List serves as a Member of Clinical Advisory Board at TetraLogic Pharmaceuticals Corporation. Dr. List has been the Chairman of Scientific Advisory Board at Cellular Biomedicine Group Inc. since July 2015. Dr. List serves as Member of Scientific Advisory Board of Amphivena Therapeutics, Inc. Dr. List serves as a Member of the Scientific Advisory Board of CytRx Oncology Corporation (formerly, Innovive Pharmaceuticals, Inc.), S*BIO Pte Ltd. and Kanisa Pharmaceuticals, Inc. Dr. List served as a Member of Scientific Advisory Board at CTI BioPharma Corp. since October 14, 2013 until January 21, 2017. Dr. List serves as a member of the Myelodysplastic Syndrome Foundation Board of Directors. Dr. List also is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; International Society for Experimental Hematology and the Southwestern Oncology Group. Dr. List receives peer-reviewed NIH support for work and publishes extensively in the areas of MDS and acute leukemia. Dr. List is the author of more than 300 peer-reviewed articles and the Clinician?s Manual on Myelodysplastic Syndromes (2008). Dr. List lectures nationally and internationally and has received several awards in recognition of seminal contributions such as induction into The Joshua Lederberg Society; the Emil J. Freireich Award for Clinical Research, M.D. Anderson (2006); the J.P. McCarthy International Prize for Advancing the Body of Scientific Knowledge in Myelodysplastic Syndrome (2004); and the General Motors Cancer Research Foundation Merit Award (1991). Dr. List completed an internship and residency in internal medicine at the Good Samaritan Medical Center in Phoenix, Arizona. Dr. List then completed fellowships in hematology and medical oncology at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. List received B.S. and M.S. degrees from Bucknell University and M.D. from the University of Pennsylvania in 1980.
Positions
- Company NameTuHURA Biosciences, Inc.Stock CodeHURAPositionIndependent DirectorColleagues
